The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Tumour cells typically exhibit a G1 cell cycle arrest in response to the MEK1/2 [mitogen-activated protein kinase/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitor selumetinib, but do not die, and thus they acquire resistance. In the present study we examined the effect of combining selumetinib with the BH3 [BCL2 (B-cell lymphoma 2) homology domain 3]-mimetic BCL2 inhibitor ABT-263. Although either drug alone caused little tumour cell death, the two agents combined to cause substantial caspase-dependent cell death and inhibit long-term clonogenic survival of colorectal cancer and melanoma cell lines with BRAFV600E or RAS mutations. This cell death absolutely required BAX (BCL2-associated X protein) and was inhibited by RNAi (RNA interference)-mediated knockdown of BIM (BCL2-interacting mediator of cell death) in the BRAFV600E-positive COLO205 cell line. When colorectal cancer cell lines were treated with selumetinib plus ABT-263 we observed a striking reduction in the incidence of cells emerging with acquired resistance to selumetinib. Similar results were observed when we combined ABT-263 with the BRAFV600E-selective inhibitor PLX4720, but only in cells expressing BRAFV600E. Finally, cancer cells in which acquired resistance to selumetinib arises through BRAFV600E amplification remained sensitive to ABT-263, whereas selumetinib-resistant HCT116 cells (KRASG13D amplification) were cross-resistant to ABT-263. Thus the combination of a BCL2 inhibitor and an ERK1/2 pathway inhibitor is synthetic lethal in ERK1/2-addicted tumour cells, delays the onset of acquired resistance and in some cases overcomes acquired resistance to selumetinib.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ABT-263 in combination with selumetinib increased caspase-dependent cell death through Bax and effectively reduced the incidence of CRC-acquired resistance to selumetinib [40].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [40]
In the citing paper
“As a result, inhibition of ERK1/2 signalling in tumour cells invariably promotes the expression of pro-apoptotic BIM, BMF and/or PUMA11.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
In the citing paper
“ERK1/2 signalling also represses BMF protein expression11,”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
In the citing paper
“Indeed, ERK1/2 pathway inhibitors combine with navitoclax, or the close analogue ABT-737, to induce colorectal cancer (CRC) apoptosis and tumour regression in vivo11,25,26.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
In the citing paper
“however, we and others have noted more limited synergy between ERK1/2 pathway inhibitors and navitoclax/ABT-737 in melanoma11,26–28.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [11]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Self-citationTargeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
Cook, S. J., Stuart, K., Gilley, R., & Sale, M. J. (2017) · The FEBS Journal · doi:10.1111/febs.14122 · Cited by 170
Self-citationERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
Self-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Perez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M. W., Bollag, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 135
“It should be noted that because several components of the Bcl-2 family of proteins have been linked to the response of cells to ABT-263/ABT-737, in particular MCL-1, BAX, and BIM (60, 61), a complex interplay between these proteins and BAD could mediate the overall resistance phenotype in response to HGF.”
BackgroundInfluentialFaber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Han, L., Zhang, Q., Dail, M., Shi, C., Cavazos, A., Ruvolo, V. R., Zhao, Y., Kim, E. S., Rahmani, M., Mak, D. H. F., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205534 · Cited by 116
“We also observed BIM induction in MV4-11 cells, underscoring its critical role in the efficacy of the combination of BCL2 and MEK inhibitors.(37,38,44) Although RPPA data showed no modulation of MCL1 after cobimetinib treatment, both western blot and Meso Scale Discovery assays showed downregulation of MCL1 in OCL-AML…”
BackgroundBH3-mimetics: recent developments in cancer therapy
Townsend, P. A., Kozhevnikova, M. V., Cexus, O., Zamyatnin, A. A., & Soond, S. M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02157-5 · Cited by 115
“CRC/Melanoma Colo-205 AZD6244 resistance – [145]”
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 80
Self-citationTan, N., Wong, M., Nannini, M. A., Hong, R., Lee, L. B., Price, S., Williams, K., Savy, P. P., Yue, P., Sampath, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0949 · Cited by 80
Jones, G. G., del Río, I. B., Sari, S., Sekerim, A., Young, L. C., Hartig, N., Areso Zubiaur, I., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 80
Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy
Mohana‐Kumaran, N., Hill, D. S., Allen, J. D., & Haass, N. K. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12242 · Cited by 64
“A more recent study confirmed the synergy of MAPK inhibitors and BH3-mimetics both for melanoma and colon cancer cells (Sale and Cook, 2013).”
BackgroundJebahi, A., Villedieu, M., Pétigny-Lechartier, C., Brotin, É., Louis, M.-H., Abeilard, E., Giffard, F., Guercio, M., Briand, M., Gauduchon, P., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.001 · Cited by 66
“Our results thus demonstrated that coupling CI-1040 with ABT-737 was not cytotoxic in the SKOV3 cell line, contrarily to that reported in B-Raf and K-Ras mutant carcinoma cells [49–51] and in acute myeloid leukaemia cells [19].”
ResultTargeting cell death signaling in colorectal cancer: Current strategies and future perspectives
Koehler, B. C., Jäger, D., & Schulze-Bergkamen, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1923 · Cited by 61
Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds
Choudhary, N., Bawari, S., Burcher, J. T., Sinha, D., Tewari, D., & Bishayee, A. (2023) · Cancers · doi:10.3390/cancers15153980 · Cited by 61
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyla, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K. D., Hughes, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09438-w · Cited by 52
Self-citationPilling, A. B., & Hwang, C. (2019) · The Prostate · doi:10.1002/pros.23843 · Cited by 54
“We focused on the BH3‐only protein BIM since it is a direct activator of BAX/BAK and a sensitizer (antagonist) to all the antiapoptotic BCL2 protein members.(18) As shown in untreated C4‐2 cells, both BIM and BAX are complexed with BCL‐xL (Figure 4A).”
Pétigny-Lechartier, C., Duboc, C., Jebahi, A., Louis, M.-H., Abeilard, E., Denoyelle, C., Gauduchon, P., Poulain, L., & Villedieu, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0342 · Cited by 57
“MEK inhibition has been reported to induce Bim (9, 43–47) and Puma expression (46) and/or to repress Mcl-1 expression (46, 48) in various cancer cell types.”
BackgroundCosta, D. B., & Kobayashi, S. S. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.05.05 · Cited by 49
“The concept of “oncogene-addiction” (11) may be the shared basis of pathogenesis for all oncogenic kinase-driven tumors (12-14).”
BackgroundDissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
Clarke, P. A., Roe, T., Swabey, K., Hobbs, S., McAndrew, C., Tomlin, K., Westwood, I. M., Burke, R., van Montfort, R., & Workman, P. (2019) · Oncogene · doi:10.1038/s41388-019-0780-z · Cited by 46
“or PI3K-inhibitors [35–37], and also block the acquisition of resistance to MEK inhibition [38].”
BackgroundFlorent, R., Weiswald, L., Lambert, B., Brotin, É., Abeilard, E., Louis, M.-H., Babin, G., Poulain, L., & N’Diaye, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2588-8 · Cited by 45
Li, H., Liu, L., Chang, H., Zou, Z., & Xing, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0169-2 · Cited by 43
Darling, N. J., Balmanno, K., & Cook, S. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184907 · Cited by 42
“Indeed, whilst selumetinib caused little or no cell death when added to COLO205 cells alone [27, 32] it inhibited constitutive ERK1/2 signalling (Fig 1D) and combined with Tg or Tm to cause a striking increase in cell death (Fig 1E).”
BackgroundMethodResultInfluentialSelf-citationGrazia, G., Penna, I., Perotti, V., Anichini, A., & Tassi, E. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2491 · Cited by 40
“Furthermore, the association of selumetinib with ABT-263, a BH3-mimetic that disrupts the interactions of Bcl-2 and Bcl-XL with proapoptotic proteins (145), also induced caspase-dependent cell death in A375 melanoma cell line (146).”
Bcl-2 family inhibitors sensitize human cancer models to therapy
Valentini, E., Martile, M. D., Brignone, M., Caprio, M. D., Manni, I., Chiappa, M., Sergio, I., Chiacchiarini, M., Bazzichetto, C., Conciatori, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05963-1 · Cited by 38
“ABT-263 synergizes with MEK1/2i and induces death in melanoma cell lines with BRAF or RAS mutations [18].”
InfluentialThe Anticancer Action of a Novel 1,2,4-Triazine Sulfonamide Derivative in Colon Cancer Cells
Gornowicz, A., Szymanowska, A., Mojzych, M., Czarnomysy, R., Bielawski, K., & Bielawska, A. (2021) · Molecules · doi:10.3390/molecules26072045 · Cited by 36
“Its mechanism of action promotes cell death and inhibits ERK kinase 1/2 [33].”
Ashford, A. L., Dunkley, T. P. J., Cockerill, M. J., Rowlinson, R. A., Baak, L., Gallo, R., Balmanno, K., Goodwin, L., Ward, R. A., Lochhead, P. A., et al. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2032-x · Cited by 35
“For example, whilst selumetinib exerts a largely cytostatic effect, combining the BH3-mimetic ABT-263 with selumetinib causes up to 80 % cell death in colorectal cells and delays the onset of acquired resistance to selumetinib [47].”
BackgroundSelf-citationMelanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 34
“The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.”
BackgroundInfluentialLeto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
“However, several preclinical studies have encouraged their use to exacerbate apoptosis in combination with oncogenic kinase small-molecule inhibitors in contexts where the effect of single-agent therapy with kinase inhibitors is limited to proliferation arrest (11, 18 – 24).”
Shrestha, N., Nimick, M., Dass, P., Rosengren, R. J., & Ashton, J. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-55376-4 · Cited by 32
Singh, P. K., Roukounakis, A., Weber, A., Das, K. K., Sohm, B., Villunger, A., García‐Sáez, A. J., & Häcker, G. A. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0365-y · Cited by 31
“Extracellular signal–regulated kinase signaling has substantial effects on the activity of Bim [19] as well as on Bmf [20].”
BackgroundSrivastava, A. K., Jaganathan, S., Stephen, L. L., Hollingshead, M. G., Layhee, A., Damour, E., Govindharajulu, J. P., Donohue, J., Esposito, D., Mapes, J. P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3156 · Cited by 30
“Clin Cancer Res; 22(4) February 15, 2016 Clinical Cancer Research 1002”
BackgroundInfluentialIntrinsic and acquired resistance to MEK1/2 inhibitors in cancer
Sale, M. J., & Cook, S. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140129 · Cited by 28
Self-citationCho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0735 · Cited by 24
“When BCL-XL is inhibited, BIM (Bcl-2 interacting mediator of cell death) is released, leading to mitochondrial-induced apoptosis in cells having increased BCL-XL expression (29, 30).”
BackgroundSale, M. J., & Cook, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12220 · Cited by 20
“Thus, at least in HCT116 cells, apoptosis in response to these agents absolutely required BAX, whereas BAK was dispensable (Sale and Cook, 2013).”
BackgroundInfluentialSelf-citationThompson, E. L., Hu, J., & Niedernhofer, L. J. (2021) · Cancers · doi:10.3390/cancers13092241 · Cited by 20
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Cai, J., Jacob, S., Kurupi, R., Dalton, K. M., Coon, C. M., Greninger, P., Egan, R. K., Stein, G. T., Murchie, E., McClanaghan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111095 · Cited by 19
“In addition, downregulation of the MEK/ERK pathway by SHP099 was sufficient to upregulate the BH3-only protein BIM, a major effector protein of this pathway in cancer (Faber et al., 2012; Sale and Cook, 2013) in both sensitive and resistant NBs (Figure 2A).”
Ebi, H., Faber, A. C., Engelman, J. A., & Yano, S. (2014) · Cancer Science · doi:10.1111/cas.12383 · Cited by 18
Targeting a chemorefractory COLO205 (BRAF V600E) cell line using substituted benzo[α]phenoxazines
Pal, S., Konkimalla, V. B., Kathawate, L., Rao, S. S., Gejji, S. P., Puranik, V. G., Weyhermüller, T., & Salunke‐Gawali, S. (2015) · RSC Advances · doi:10.1039/c5ra14949e · Cited by 12
Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells
Hur, E., Goo, B.-K., Moon, J., Choi, Y., Hwang, J. J., Kim, C., Bae, K., Choi, J., Cho, S. Y., Yang, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17866 · Cited by 10
“Furthermore, a combination of AZD6244 and an BCL2 inhibitor (ABT-263) was shown to be synergistic in causing a cell death response in colon cancer or melanoma cells harboring B-RAF or RAS mutations, and also to delay the onset of acquired resistance and in some cases overcome acquired resistance to AZD6244 [40].”
BackgroundEmbracing synthetic lethality of novel anticancer therapies
Kamal, Ä., Shaik, T. B., & Malik, M. S. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1072167 · Cited by 10
“The MEK inhibition leads to initiation of Bim and the results demonstrated that the antiapoptotic protein such as Bcl-XL was inhibited by increased levels of Bim.”
BackgroundInfluentialSMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors
Kiga, M., Nakayama, A., Shikata, Y., Sasazawa, Y., Murakami, R., Nakanishi, T., Tashiro, E., & Imoto, M. (2015) · Scientific Reports · doi:10.1038/srep08155 · Cited by 9
Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
Yu, R., Lu, Y.-F., Ren, Y., Xie, J., & Zhou, S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s265788 · Cited by 9
Sahoo, S., Suvarna, S., Chandra, A., Wahi, S., Kumar, P., & Khanna, G. (2013) · PubMed · Cited by 9
Sale, M. J., & Cook, S. J. (2014) · Biochemical Journal · doi:10.1042/bj20131346 · Cited by 6
Self-citationSensitivity and Resistance to BH3 Mimetics in Cancer Therapy
Floros, K. V., Faber, A. C., & Harada, H. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_7 · Cited by 1
Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments
Venerando, A., Lovison, D., & Marco, R. D. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00074 · Cited by 1
Moving Forward: Making BRAF-Targeted Therapy Better
Flaherty, K. T. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4939-2143-0_9
Kaur, K., Singh, S. J., Zecena, H., Dejean, L. M., & Filipp, F. V. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3155715
Teachey, D. T. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735832437.793581828
van der Zwet, J. C. G. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1098
El‐Deiry, W. S., & Borerro, L. H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735662150.793560370
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1
Xu, J., Liu, L., Liu, S., He, Z., & Meng, W. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02344-9
“As resistance to MEK inhibition remains a major barrier and effective counterstrategies are still lack - ing, elucidating its underlying mechanisms and developing new therapeutic approaches are urgently needed [ 9 ].”
Metadata
- Authors
- Sale, M. J., & Cook, S. J.
- Affiliations
- Babraham Institute (GB)
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2013-02-15
- Volume
- 450
- Issue
- 2
- Pages
- 285-294
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2316080015
- Cited by
- 58
- References
- 50
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 9 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 11 · 2014: 8 · 2013: 5
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (C488/A14867, 14867)
- Biotechnology and Biological Sciences Research Council (BB/E02162X/1, BB/F0158521/1, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- navitoclax, selumetinib, BH3 mimetics, BCL-2 inhibitor, MEK inhibitors, acquired drug resistance, building information modeling, Bax, caspase-dependent cell death, synthetic lethality, BRAF V600E mutation, RAS mutations, colorectal cancer, melanoma, PLX4720, combination therapy
- MeSH terms
- Aniline Compounds, Benzimidazoles, Humans, Sulfonamides, Cell Death, Apoptosis, Drug Resistance, Neoplasm, HT29 Cells, MAP Kinase Signaling System, RNA Interference, Cell Line, Tumor, MAP Kinase Kinase 1, MAP Kinase Kinase 2, bcl-2-Associated X Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.